ArticleBMC pulmonary medicine2026
Thiamine supplementation is associated with lower in-hospital and ICU mortality in patients with acute respiratory failure: a retrospective cohort study based on the MIMIC-IV database.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThiamine (vitamin B1), a cofactor in energy metabolism and antioxidant pathways, may mitigate mitochondrial dysfunction in critical illnesses. However, its association with outcomes in acute respiratory failure (ARF) remains underexplored. This study investigated whether thiamine supplementation is associated with survival in ARF patients.
methodsUsing data from the MIMIC-IV database, we conducted a retrospective cohort study of 2805 ARF patients admitted to the ICU between 2008 and 2019. Patients were stratified into thiamine group (n = 615) and no thiamine group (n = 2190) groups. Primary endpoints were in-hospital and ICU mortality. The relationship between thiamine supplementation and these outcomes was evaluated using Kaplan-Meier survival curves, Cox proportional hazards regression, propensity score matching (PSM), and subgroup analyses.Among patients receiving thiamine, we further explored the association between treatment duration (≥ 6 days vs. <6 days) and mortality.
resultsKaplan-Meier curves showed significantly higher survival in the thiamine group. After multivariable adjustment (Model II), no thiamine use was associated with increased mortality risk (in-hospital mortality: HR = 1.28, 95%CI 1.11–1.70; ICU mortality: HR = 1.52, 95%CI 1.18–1.96). Consistent results were observed in the PSM cohort (n = 1,054; in-hospital mortality: HR = 1.39, 95%CI 1.06–1.84; ICU mortality: HR = 1.54, 95%CI 1.09–2.14). Among thiamine recipients, treatment duration ≥ 6 days (n = 195) was associated with significantly lower mortality compared to shorter duration (in-hospital mortality: HR = 2.39, 95%CI 1.55–3.68; ICU mortality: HR = 3.27, 95%CI 1.86–5.72). Subgroup analysis revealed that patients aged ≥ 60 years exhibited a more pronounced association between thiamine use and lower mortality (in-hospital mortality: HR = 1.68, 95%CI 1.29–2.19; ICU mortality: HR = 1.89, 95%CI 1.37–2.61).
conclusionIn this ICU cohort, early thiamine supplementation was independently associated with lower mortality in ARF patients, with a more pronounced association observed in elderly patients. Longer treatment duration (≥ 6 days) was associated with greater survival benefit among thiamine recipients. These hypothesis-generating findings warrant validation through randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.